Single dose vaccine delivery system of tetanus toxoid formulation based on chitosan microsp

Authors

  • Dineshkumar B Dept. of Pharmaceutical Biotechnology, J.S.S College of Pharmacy, Rocklands, Ootacamund, TN 643 001, India
  • Dhanaraj S.A Dhanaraj S.A School of Pharmacy Faculty of Medicine and Health Sciences AIMST University, Malaysia 08100. H/P:0060-16-4346204.
  • Santhi K Dhanaraj S.A School of Pharmacy Faculty of Medicine and Health Sciences AIMST University, Malaysia 08100. H/P:0060-16-4346204.
  • Vijayan P Dept. of Pharmaceutical Biotechnology, J.S.S College of Pharmacy, Rocklands, Ootacamund, TN 643 001, India
  • Raghu Chandrasekhar Dept. of Pharmaceutical Biotechnology, Manipal University, Manipal 576104, Karnataka, India

Keywords:

Tetanus toxoid, Chitosan microspheres, Single shot vaccine

Abstract

Background: Biodegradable polymers such as Chitosan or PLGA has been used for sustain release of vaccines for prolonged period. Purpose of the study: To develop single dose vaccine delivery system of tetanus toxoid using chitosan microspheres. Different batches, 1%, 2% and 3% of chitosan microspheres (CM) were prepared by emulsion cross-linking method using glutaradehyde saturated toluene (GST). The tetanus toxoid (TT) was loaded with 1%, 2% and 3% of CM by adsorption method. Percentage of TT absorbed in 1%, 2% and 3% CM were determined by Limes flocculation method. In vitro release of adsorbed TT from 1%, 2% and 3% CM were performed with PBS (pH 7.4) and evaluated by ELISA assay using purified guinea pig IgG by affinity chromatography. Results: The average particle size of 1%, 2% and 3% of CM were determined by optical microscopic method and particle size was found to be 30µm, 31µm, and 35µm respectively. Percentage of TT adsorbed in 1%, 2% and 3% CM were found to be 71%, 80% and 76% respectively by Limes flocculation method. In vitro studies showed that different batches (1%, 2% and 3%) of CM showed cumulative percentage release of TT 74.09%, 89.31%, and 80.23% respectively for 50 days. Among three batches of microspheres, 2% of chitosan microspheres showed better consistent and sustained release of TT for 50 days. Conclusions: This study suggested that 2% of chitosan microspheres could be useful for sustained release of tetanus toxoid to maintain the antibody titre for prolonged period.

References

Galazka AM. The immunological basis for

immunization series. Module 3: tetanus. Geneva:

World Health Organization, Global programme for

vaccines and immunization: expanded programme

on immunization. 1993;WHO/EP/GEN/93:13.

Aguado M. Future approaches to vaccine

development: single-dose vaccine using controlled

release delivery system, Vaccine 1993; 11: 596-

Okada H, Toguchi H. Biodegradable microspheres

in drug delivery. Crit Rev Ther Drug Carrier Syst

;12: 1–99.

Aguado M, Lambert P. Controlled release

vaccines: biodegradable polylactide/ployglycolide

PL/PG) microspheres as antigen vehicles.

Immunology 1992; 84: 113-125.

Calvo P, Remunan-Lopez C, Vila-Jato JL, Alonso

MJ. Chitosan and chitosan/ethylene oxidepropylene oxide block copolymer nanoparticles as

novel carriers for proteins and vaccines. Pharm Res

;14: 1431–1436.

Remunan-Lopez C, Bodmeier R. Effect of

formulation and process variables on the formation

of chitosan–gelatin coacervates. Int J Pharm

;136: 63–72.

Determination of limes flocculation of Diphtheria

toxin. Diphtheria toxoid. Diphtheria vaccine and

tetanus vaccine. Indian Pharmacopeia; 1996.

Volume 2, p. 29-33.

Jaganathan KS, Rao YUB, Singh P, Prabakaran

D, Gupta S, Jain A, Vyas SP. Development of

single dose tetanus toxoid formulation based on

polymeric microspheres; comparative studies of

poly(D,L-lactic-co-glycolic acid) versus chitosan

microspheres. Int J Pharm 2005;294: 23-32.

Xing DKL, Crane DT, Bolgiano B, Corbel MJ,

Jones C, Sesardic D. Physicochemical and

immunological studies on the stability of free and

microspheres-encapsulated tetanus toxoid in

vitro. Vaccine 1996;14: 1205-1213.

Johansen P, Merkle HP, Gander B. Physicochemical and antigenic properties of tetanus and

diphtheria toxoids and steps towards improved

stability. Biochimica et Biophysica Acta

;1425: 425-436.

Esparza I, Kissel T. Parameters affecting the

immunogenicity of microencapsulated tetanus

toxoid. Vaccine 1992;10: 714-720.

Raghuvanshi RS, Katare YK, Lalwani K, Ali MM,

Singh O, Panda AK. Improved immune response

from biodegradable polymer particles entrapping

tetanus toxoid by use of different immunization

protocol and adjuvants. Int J Pharm 2002;245:

-121.

Johansen P, Corradin G, Merkle HP, Gander B.

Release of tetanus toxoid from adjuvants and

OLGA microspheres: How experimental set-up

and surface adsorption fool the pattern. J

Controlled Release 1998;56: 209-217.

Sanchez A, Villamayor B, Guo Y, McIver J,

Alonso MJ. Formulation strategies for the

stabilization of tetanus toxoid in poly (lactide-coglycolide) microspheres. Int J Pharm 1999; 185:

-266.

Sasiak AB, Bolgiano B, Crane DT, Hockley DJ,

Corbel MJ, Sesardic D. Comparison of in viro and

in vivo methods to study stability of PLGA

microencapsulated tetanus toxoid vaccines.

Vaccine 2001;19: 694-705.

Johansen P, Tamber H, Merkle HP, Gander B.

Diphtheria and tetanus toxoid microencapsulation

into conventional and end-group alkylated

PLA/PLGAs. Eur J Pharm Biopharm 1999;47:

-201.

Manghi MA, Pasetti MF, Brero ML, Deluchi S,

Paola GD, Mathet V, Eriksson PV. Development

of an ELISA for measuring the activity of tetanus

toxoids in vaccines and comparision with the toxin

neutralization test in mice. J Immunol Methods

;168: 17-24.

Jung T, Koneberg R, Hungerer K.D, Kissel T.

Tetanus toxoid microspheres consisting of

biodegradable poly(lactic-co-glycolide) and ABAtriblock-copolymers: immune response in mice.

Int J Pharm 2002; 234:75-90.

Downloads

Published

03/31/2010

Issue

Section

Original Research Articles